Sibylla inks drug discovery collaboration with Ono Pharma to develop candidates for multiple therapeutics in CNS disorders
Sibylla Biotech announced a drug discovery collaboration with Osaka-headquartered Ono Pharmaceutical Co., for accessing Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop candidates for multiple therapeutic targets in the field of central nervous system (CNS) disorders.
Terms of Agreement
Under the terms of the collaboration, Sibylla is entitled to a total deal value in the three-digit millions of US dollars, including upfront payment, research, development and sales milestones, and royalties on sales. Further financial details on the collaboration have not been disclosed.
Sibylla Biotech’s Technology
- Sibylla Biotech utilizes its PPI-FIT technology to design Folding Interfering Degraders (FIDs).
- FIDs are small molecules that induce the degradation of a target protein by interfering with its folding pathway. The technology targets specific proteins, particularly those considered “undruggable” due to the absence of suitable pockets in their native state.
- Ono Pharmaceutical plans to harness this technology to address some of the most challenging aspects of CNS drug development by targeting proteins involved in complex neurological pathways.
Words from Ono Pharma
“Sibylla's PPI-FIT technology platform has the potential to surpass the limitations of conventional methods and uncover novel CNS therapeutic targets,” said Toichi Takino, senior executive officer/executive director, discovery & research of Ono Pharmaceutical. “This collaboration is a key part of our strategy to increase efficiency in developing our pipeline in CNS areas and bring innovative solutions to patients facing serious neurological disorders.”
Words from CEO: Sibylla Biotech
“Our partnership with Ono Pharmaceutical represents a fusion of Sibylla's cutting-edge technology in protein folding simulation with Ono's extensive experience in CNS research. Together, we aim to unlock new therapeutic possibilities for patients worldwide,” commented Lidia Pieri, PhD, co-founder and chief executive officer of Sibylla Biotech. “I am honored to collaborate with the Ono Pharmaceutical team, whose rich history, expertise and culture I greatly appreciate, and all of us at Sibylla look forward to working closely with them.
